



(51) International Patent Classification:

C07D 471/20 (2006.01) *A61P 33/02* (2006.01)
C07D 487/20 (2006.01) *A61P 33/06* (2006.01)
A61K 31/437 (2006.01) *A61K 31/424* (2006.01)
A61K 31/55 (2006.01) *A61K 31/438* (2006.01)
A61K 31/407 (2006.01) *C07D 498/22* (2006.01)

(21) International Application Number:

PCT/EP2009/053902

(22) International Filing Date:

1 April 2009 (01.04.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

08155342.2 29 April 2008 (29.04.2008) EP
 09151117.0 22 January 2009 (22.01.2009) EP

(71) Applicant (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ANG, Shi Hua** [SG/SG]; Novartis Institute for Tropical Diseases Pte Ltd, 10 Biopolis Road, #05-01 Chromos, Singapore 138670 (SG). **KRASTEL, Philipp** [DE/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **LEONG, Seh Yong** [SG/SG]; Novartis Institute for Tropical Diseases Pte Ltd, 10 Biopolis Road, #05-01 Chromos, Singapore 138670 (SG). **TAN, Liying Jocelyn** [SG/SG]; Novartis Institute for Tropical Diseases Pte Ltd, 10 Biopolis Road, #05-01 Chromos, Singapore 138670 (SG). **WONG, Wei Lin Josephine** [SG/SG]; Novartis Institute for Tropical Diseases Pte Ltd, 10 Biopolis Road, #05-01 Chromos, Singapore 138670 (SG). **YEUNG, Bryan KS** [US/SG]; Novartis Institute for Tropical Diseases Pte Ltd, 10 Biopolis

Road, #05-01 Chromos, Singapore 138670 (SG). **ZOU, Bin** [CN/SG]; Novartis Institute for Tropical Diseases Pte Ltd, 10 Biopolis Road, #05-01 Chromos, Singapore 138670 (SG).

(74) Agent: **ROSS, Richard A. M.**; Novartis Pharma AG, Patent Department, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: SPIRO-INDOLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES



(57) Abstract: The invention relates to organic compounds which have interesting pharmaceutical properties. In particular, the compounds are useful in the treatment and/or prevention of infections such as those caused by *Plasmodium falciparum*, *Plasmodium vivax*, *Plasmodium malariae*, *Plasmodium ovale*, *Trypanosoma cruzi* and parasites of the *Leishmania* genus such as, for example, *Leishmania donovani*. The invention also relates to pharmaceutical compositions containing the compounds, as well as processes for their preparation.